Ontology highlight
ABSTRACT: Background
Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the same indications as the reference product; however, the approval was based on extrapolated data from rheumatoid arthritis and ankylosing spondylitis. Our aim was to review clinical studies about switching from originator infliximab (IFX-O) to biosimilar infliximab (IXF-B) in IBD, focusing on recently published data and the future of biosimilars.Methods
The PubMed database was searched for original articles published up to 1 December 2018 reporting data on IFX-B in IBD.Results
A total of 29 studies assessing switching
SUBMITTER: Milassin A
PROVIDER: S-EPMC6469269 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature